Findings

What do systematic reviews say?

6 questions · 8 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 2 · 25%High 3 · 37.5%

Low molecular weight heparin vs active control

Symptomatic VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in symptomatic VTE compared with with active control (1) (low certainty).

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 2.89 [0.12, 66.75]
1 study · 51 participants
Low
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.51 [0.22, 1.17]
2 studies · 781 participants
Moderate
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.33 [0.14, 0.83]
1 study · 439 participants
High

Low molecular weight heparin vs no thromboprophylaxis

Symptomatic VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin leads to lower symptomatic VTE compared with no thromboprophylaxis (high certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.62 [0.46, 0.83]
11 studies · 3931 participants
High

Ultra‐low‐molecular‐weight heparin vs placebo

Symptomatic VTE · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin leads to lower symptomatic VTE compared with placebo (high certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.36 [0.22, 0.6]
1 study · 3212 participants
High

Subcutaneous unfractionated heparin vs low molecular weight heparin

Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

The review found no eligible studies for this question.

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Subcutaneous unfractionated heparin vs low molecular weight heparin

Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 1.01 [0.63, 1.63]
5 studies · 2156 participants
Low

Intervention not reported

Symptomatic VTE · patients undergoing abdominal or pelvic surgery

The intervention showed no clear difference in symptomatic VTE (moderate certainty).

1 finding from 1 review

Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery 2019 · Cochrane Headline outcomes only
OR 0 [0.08, 1.11]
7 studies · 1728 participants
Moderate